Related Concept Videos
01:29Chronic Obstructive Pulmonary Disease-V: Management
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
01:20Chronic Obstructive Pulmonary Disease-I: Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
01:24Chronic Obstructive Pulmonary Disease
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
01:24Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features
Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
You might also read
Related Articles
Articles linked to this work by shared authors, journal, and citation graph.
Sort by
Same author
Timely management of COPD exacerbations is associated with limited acute deterioration and early recovery: a prospective observational study.
Respiratory research·2026
Same author
Evolution toward early stent removal and reduced antibiotic prophylaxis post-cystectomy.
The Canadian journal of urology·2026
Same author
From evidence to implementation: key priorities for pharmacogenomics-guided treatment and prevention from a European expert workshop.
European journal of human genetics : EJHG·2026
Related Experiment Video
Updated: May 28, 2026
04:03
Alternative Therapy for Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Moving Cupping Along Meridians
Published on: September 27, 2024
Utility estimation in chronic obstructive pulmonary disease: a preference for change?
Jennifer Petrillo1, Floortje van Nooten, Paul Jones
1Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK. jennifer.petrillo@lshtm.ac.uk
Pharmacoeconomics
|October 13, 2011
Summary
Generic health measures like EQ-5D show limited sensitivity in chronic obstructive pulmonary disease (COPD), potentially biasing economic analyses. Condition-specific tools may offer better insights into patient quality of life.
Area of Science:
- Health Economics
- Pulmonary Medicine
- Quality of Life Research
Background:
- Economic evaluations of chronic obstructive pulmonary disease (COPD) rely on multi-attribute utility (MAU) measures, frequently the EQ-5D, to assess health-related quality of life (HR-QOL).
- Concerns exist regarding the sensitivity of these generic MAU measures in capturing meaningful HR-QOL changes in COPD patients, potentially underestimating treatment benefits.
Purpose of the Study:
- To review and discuss empirical evidence on the validity and sensitivity of generic MAU measures in the COPD population.
- To evaluate the performance of these measures in stable COPD, during exacerbations, and over time.
Main Methods:
- Literature search of PubMed and EMBASE databases (1988-2009) using keywords related to respiratory disease and EQ-5D.
- Analysis of existing studies evaluating the performance of generic MAU measures in COPD patients.
Main Results:
- Generic MAU measures demonstrate limited ability to discriminate between moderate and severe COPD, despite known HR-QOL differences.
- Sensitivity to clinically relevant changes in HR-QOL over time in stable COPD appears restricted.
- Responsiveness to exacerbations is adequate for onset/resolution but limited for short-term or subtle daily changes, often requiring large within-patient changes.
Conclusions:
- The insensitivity of generic MAU measures in COPD can lead to biased cost-effectiveness analyses and suboptimal economic decision-making.
- Condition-specific, preference-based measures may be more appropriate for sensitive evaluation of COPD patient outcomes.
- While condition-specific measures offer greater sensitivity, they may not capture all relevant aspects, such as adverse events.